Quarterly report pursuant to Section 13 or 15(d)

11. Related Party Transactions (Details Narrative)

v3.20.2
11. Related Party Transactions (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Research and development expense $ 307,900 $ 487,519 $ 667,551 $ 951,301  
Advanced payment 1,049,339   1,049,339   $ 722,079
Hesperix [Member]          
Repayment of loan         225,000
Pharmsynthez [Member] | Sponsored Research Agreement [Member]          
Research and development expense     100,000    
Payment for research agreement         350,000
Advanced payment 100,000   100,000   200,000
Pharmsynthez [Member] | Co-Development Agreement [Member]          
Payment for note receivable         $ 500,000
Note receivable outstanding $ 500,000   $ 500,000    
Note receivable interest rate 10.00%   10.00%    
Interest income $ 13,000   $ 25,000